Journal of Immunology Research

Immunotherapy and Vaccine Development


Status
Published

Lead Editor

1University of Oxford, Oxford, UK

2University of Zürich, Zürich, Switzerland

3German Cancer Research Center (DKFZ), Heidelberg, Germany


Immunotherapy and Vaccine Development

Description

The success of immune checkpoint inhibitors for the treatment of cancer represents a new era for cancer treatment. The field is currently blooming with various clinical approaches in development including chimeric antigen receptor T cell therapy and prophylactic cancer vaccines against cervical cancer. However, the side effects of these therapies and the failure to extend the success of the cervical cancer vaccines to other cancers spark more questions. A better understanding of the immunological mechanisms towards different immunotherapies and vaccination will advance the development and extend the therapies to other diseases.

We invite investigators to submit original research and review articles that will contribute to the understanding and development of immunotherapy and vaccine research. We are particularly interested in articles testing novel and effective immunotherapies, giving new insights into the mechanisms involved in the therapy.

Potential topics include but are not limited to the following:

  • T cell based immunotherapies and vaccines
  • Immunotherapy for cancer and infectious diseases
  • Immunotherapy for autoimmune diseases
  • Development of prophylactic vaccines against cancer and infectious diseases
  • Animal models for studying immunotherapies and vaccine strategies
  • Vaccine adjuvants

Articles

  • Special Issue
  • - Volume 2018
  • - Article ID 8751027
  • - Editorial

Immunotherapy and Vaccine Development

Carol Leung | Christian Münz | Angelika Riemer
  • Special Issue
  • - Volume 2018
  • - Article ID 2480931
  • - Research Article

Analysis of ROR1 Protein Expression in Mice with Reconstituted Human Immune System Components

Carol S. Leung
  • Special Issue
  • - Volume 2018
  • - Article ID 2386187
  • - Review Article

Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies

Shangjun Sun | He Hao | ... | Yang Fu
  • Special Issue
  • - Volume 2018
  • - Article ID 3525302
  • - Research Article

Mycobacterium tuberculosis Protein Rv3841 Activates Dendritic Cells and Contributes to a T Helper 1 Immune Response

Seunga Choi | Han-Gyu Choi | ... | Hwa-Jung Kim
  • Special Issue
  • - Volume 2018
  • - Article ID 3487095
  • - Research Article

Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice

Suvi Heinimäki | Maria Malm | ... | Vesna Blazevic
  • Special Issue
  • - Volume 2018
  • - Article ID 3710961
  • - Research Article

Leaf-Encapsulated Vaccines: Agroinfiltration and Transient Expression of the Antigen Staphylococcal Endotoxin B in Radish Leaves

Pei-Feng Liu | Yanhan Wang | ... | Chun-Ming Huang
  • Special Issue
  • - Volume 2017
  • - Article ID 6940546
  • - Review Article

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma

Fu-Shun Hsu | Chun-Hung Su | Kou-How Huang
  • Special Issue
  • - Volume 2017
  • - Article ID 7983217
  • - Research Article

Targeting of Immune Cells by Dual TLR2/7 Ligands Suppresses Features of Allergic Th2 Immune Responses in Mice

Jonathan Laiño | Andrea Wangorsch | ... | Stefan Schülke
  • Special Issue
  • - Volume 2017
  • - Article ID 5689709
  • - Research Article

Immunization with Bivalent Flagellin Protects Mice against Fatal Pseudomonas aeruginosa Pneumonia

Bahador Behrouz | Farhad B. Hashemi | ... | Abbas Ali Imani Fooladi
  • Special Issue
  • - Volume 2017
  • - Article ID 3736201
  • - Review Article

Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials

Ana Paula Ferreira Costa | Ricardo Ney Oliveira Cobucci | ... | Ana Katherine Gonçalves
Journal of Immunology Research
 Journal metrics
Acceptance rate45%
Submission to final decision61 days
Acceptance to publication37 days
CiteScore5.100
Impact Factor3.327
 Submit